GLG Partners’s Matinas BioPharma MTNB Stock Holding History

GLG Partners’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-699	Closed	-$97K	–	391
2017 Q1	$97K	Buy	+699	New	+$114K	﹤0.01%	421

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AWMG

Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

GLG Partners's MTNB Position: Q2 2017 in Review

GLG Partners sold out of Matinas BioPharma (MTNB) in Q2 2017, closing a stake of 699 shares — an estimated $97K sold.

GLG Partners first reported a position in MTNB in Q1 2017 and held it in 1 quarter. The position peaked at $97K in Q1 2017. 45 funds tracked by Wall St. Rank hold MTNB as of Q2 2017.

GLG Partners reported no remaining Matinas BioPharma position as of Q2 2017 after selling out during the quarter.
GLG Partners sold 699 Matinas BioPharma shares in Q2 2017, an estimated $97K.
GLG Partners first reported a position in Matinas BioPharma in Q1 2017 and held it in 1 quarter.
GLG Partners's Matinas BioPharma position peaked at $97K in Q1 2017.
45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.